A transmission-virulence evolutionary trade-off explains attenuation of HIV-1 in Uganda

  1. François Blanquart  Is a corresponding author
  2. Mary Kate Grabowski
  3. Joshua Herbeck
  4. Fred Nalugoda
  5. David Serwadda
  6. Michael A Eller
  7. Merlin L Robb
  8. Ronald Gray
  9. Godfrey Kigozi
  10. Oliver Laeyendecker
  11. Katrina A Lythgoe
  12. Gertrude Nakigozi
  13. Thomas C Quinn
  14. Steven J Reynolds
  15. Maria J Wawer
  16. Christophe Fraser
  1. Imperial College London, United Kingdom
  2. Johns Hopkins University, United States
  3. University of Washington, United States
  4. Rakai Health Sciences Program, Uganda
  5. Walter Reed Army Institute of Research, United States
  6. National Institutes of Health, United States

Abstract

Evolutionary theory hypothesizes that intermediate virulence maximizes pathogen fitness as a result of a trade-off between virulence and transmission, but empirical evidence remains scarce. We bridge this gap using data from a large and long-standing HIV-1 prospective cohort, in Uganda. We use an epidemiological-evolutionary model parameterised with this data to derive evolutionary predictions based on analysis and detailed individual-based simulations. We robustly predict stabilising selection towards a low level of virulence, and rapid attenuation of the virus. Accordingly, set-point viral load, the most common measure of virulence, has declined in the last 20 years. Our model also predicts that subtype A is slowly outcompeting subtype D, with both subtypes becoming less virulent, as observed in the data. Reduction of set-point viral loads should have resulted in a 20% reduction in incidence, and a three years extension of untreated asymptomatic infection, increasing opportunities for timely treatment of infected individuals.

Data availability

The following data sets were generated

Article and author information

Author details

  1. François Blanquart

    MRC Centre for Outbreak Analysis and Modelling, School of Public Health, Imperial College London, London, United Kingdom
    For correspondence
    f.blanquart@imperial.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0591-2466
  2. Mary Kate Grabowski

    Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Joshua Herbeck

    International Clinical Research Center, University of Washington, Seattle, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4577-7406
  4. Fred Nalugoda

    Rakai Health Sciences Program, Entebbe, Uganda
    Competing interests
    The authors declare that no competing interests exist.
  5. David Serwadda

    Rakai Health Sciences Program, Entebbe, Uganda
    Competing interests
    The authors declare that no competing interests exist.
  6. Michael A Eller

    U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Merlin L Robb

    U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Ronald Gray

    Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Godfrey Kigozi

    Rakai Health Sciences Program, Entebbe, Uganda
    Competing interests
    The authors declare that no competing interests exist.
  10. Oliver Laeyendecker

    Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Katrina A Lythgoe

    MRC Centre for Outbreak Analysis and Modelling, School of Public Health, Imperial College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  12. Gertrude Nakigozi

    Rakai Health Sciences Program, Entebbe, Uganda
    Competing interests
    The authors declare that no competing interests exist.
  13. Thomas C Quinn

    Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Steven J Reynolds

    Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, United States
    Competing interests
    The authors declare that no competing interests exist.
  15. Maria J Wawer

    Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, United States
    Competing interests
    The authors declare that no competing interests exist.
  16. Christophe Fraser

    MRC Centre for Outbreak Analysis and Modelling, School of Public Health, Imperial College London, London, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.

Funding

European Commission (Intra European Fellowship 657768)

  • François Blanquart

World Bank Group

  • Mary Kate Grabowski
  • Fred Nalugoda
  • David Serwadda
  • Michael A Eller
  • Merlin L Robb
  • Ronald Gray
  • Godfrey Kigozi
  • Oliver Laeyendecker
  • Gertrude Nakigozi
  • Thomas C Quinn
  • Steven J Reynolds
  • Maria J Wawer

Henry M. Jackson Foundation (W81XWH-07-2-0067)

  • Mary Kate Grabowski
  • Fred Nalugoda
  • David Serwadda
  • Michael A Eller
  • Merlin L Robb
  • Ronald Gray
  • Godfrey Kigozi
  • Oliver Laeyendecker
  • Gertrude Nakigozi
  • Thomas C Quinn
  • Steven J Reynolds
  • Maria J Wawer

U.S. Department of Defense (W81XWH-07-2-0067)

  • Mary Kate Grabowski
  • Fred Nalugoda
  • David Serwadda
  • Michael A Eller
  • Merlin L Robb
  • Ronald Gray
  • Godfrey Kigozi
  • Oliver Laeyendecker
  • Gertrude Nakigozi
  • Thomas C Quinn
  • Steven J Reynolds
  • Maria J Wawer

National Institutes of Health (R01AI108490; P30AI027757)

  • Joshua Herbeck

European Research Council (PBDR-339251)

  • Christophe Fraser

National Institute of Allergy and Infectious Diseases (R01 Al 29314; R01 AI34826; UO1 AI11171-01-02)

  • Mary Kate Grabowski
  • Fred Nalugoda
  • David Serwadda
  • Michael A Eller
  • Merlin L Robb
  • Ronald Gray
  • Godfrey Kigozi
  • Oliver Laeyendecker
  • Gertrude Nakigozi
  • Thomas C Quinn
  • Steven J Reynolds
  • Maria J Wawer

National Institute of Child Health and Human Development (5P30 HD 06268)

  • Mary Kate Grabowski
  • Fred Nalugoda
  • David Serwadda
  • Michael A Eller
  • Merlin L Robb
  • Ronald Gray
  • Godfrey Kigozi
  • Oliver Laeyendecker
  • Gertrude Nakigozi
  • Thomas C Quinn
  • Steven J Reynolds
  • Maria J Wawer

John E. Fogarty Foundation for Persons with Intellectual and Developmental Disabilities (5D43TW00010)

  • Mary Kate Grabowski
  • Fred Nalugoda
  • David Serwadda
  • Michael A Eller
  • Merlin L Robb
  • Ronald Gray
  • Godfrey Kigozi
  • Oliver Laeyendecker
  • Gertrude Nakigozi
  • Thomas C Quinn
  • Steven J Reynolds
  • Maria J Wawer

John Snow Inc. (5024-30)

  • Mary Kate Grabowski
  • Fred Nalugoda
  • David Serwadda
  • Michael A Eller
  • Merlin L Robb
  • Ronald Gray
  • Godfrey Kigozi
  • Oliver Laeyendecker
  • Gertrude Nakigozi
  • Thomas C Quinn
  • Steven J Reynolds
  • Maria J Wawer

Pfizer (5024-30)

  • Mary Kate Grabowski
  • Fred Nalugoda
  • David Serwadda
  • Michael A Eller
  • Merlin L Robb
  • Ronald Gray
  • Godfrey Kigozi
  • Oliver Laeyendecker
  • Gertrude Nakigozi
  • Thomas C Quinn
  • Steven J Reynolds
  • Maria J Wawer

Rockefeller Foundation

  • Mary Kate Grabowski
  • Fred Nalugoda
  • David Serwadda
  • Michael A Eller
  • Merlin L Robb
  • Ronald Gray
  • Godfrey Kigozi
  • Oliver Laeyendecker
  • Gertrude Nakigozi
  • Thomas C Quinn
  • Steven J Reynolds
  • Maria J Wawer

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Informed consent was obtained from all the participants in the Rakai Community Cohort Study.The Scientific and Ethics Committee of the Uganda Virus Research Institute (UVRI) of the Ministry of Health provides the Institutional Review Board approval and monitoring of all Rakai research.

Reviewing Editor

  1. Richard A Neher, Max Planck Institute for Developmental Biology, Germany

Version history

  1. Received: August 10, 2016
  2. Accepted: November 1, 2016
  3. Accepted Manuscript published: November 5, 2016 (version 1)
  4. Accepted Manuscript updated: November 8, 2016 (version 2)
  5. Version of Record published: November 18, 2016 (version 3)

Copyright

© 2016, Blanquart et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 6,442
    Page views
  • 638
    Downloads
  • 37
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. François Blanquart
  2. Mary Kate Grabowski
  3. Joshua Herbeck
  4. Fred Nalugoda
  5. David Serwadda
  6. Michael A Eller
  7. Merlin L Robb
  8. Ronald Gray
  9. Godfrey Kigozi
  10. Oliver Laeyendecker
  11. Katrina A Lythgoe
  12. Gertrude Nakigozi
  13. Thomas C Quinn
  14. Steven J Reynolds
  15. Maria J Wawer
  16. Christophe Fraser
(2016)
A transmission-virulence evolutionary trade-off explains attenuation of HIV-1 in Uganda
eLife 5:e20492.
https://doi.org/10.7554/eLife.20492

Further reading

    1. Epidemiology and Global Health
    Charumathi Sabanayagam, Feng He ... Ching Yu Cheng
    Research Article Updated

    Background:

    Machine learning (ML) techniques improve disease prediction by identifying the most relevant features in multidimensional data. We compared the accuracy of ML algorithms for predicting incident diabetic kidney disease (DKD).

    Methods:

    We utilized longitudinal data from 1365 Chinese, Malay, and Indian participants aged 40–80 y with diabetes but free of DKD who participated in the baseline and 6-year follow-up visit of the Singapore Epidemiology of Eye Diseases Study (2004–2017). Incident DKD (11.9%) was defined as an estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2 with at least 25% decrease in eGFR at follow-up from baseline. A total of 339 features, including participant characteristics, retinal imaging, and genetic and blood metabolites, were used as predictors. Performances of several ML models were compared to each other and to logistic regression (LR) model based on established features of DKD (age, sex, ethnicity, duration of diabetes, systolic blood pressure, HbA1c, and body mass index) using area under the receiver operating characteristic curve (AUC).

    Results:

    ML model Elastic Net (EN) had the best AUC (95% CI) of 0.851 (0.847–0.856), which was 7.0% relatively higher than by LR 0.795 (0.790–0.801). Sensitivity and specificity of EN were 88.2 and 65.9% vs. 73.0 and 72.8% by LR. The top 15 predictors included age, ethnicity, antidiabetic medication, hypertension, diabetic retinopathy, systolic blood pressure, HbA1c, eGFR, and metabolites related to lipids, lipoproteins, fatty acids, and ketone bodies.

    Conclusions:

    Our results showed that ML, together with feature selection, improves prediction accuracy of DKD risk in an asymptomatic stable population and identifies novel risk factors, including metabolites.

    Funding:

    This study was supported by the National Medical Research Council, NMRC/OFLCG/001/2017 and NMRC/HCSAINV/MOH-001019-00. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

    1. Epidemiology and Global Health
    C Kim, Benjamin Chen ... RECOVER Mechanistic Pathways Task Force
    Review Article

    The NIH-funded RECOVER study is collecting clinical data on patients who experience a SARS-CoV-2 infection. As patient representatives of the RECOVER Initiative’s Mechanistic Pathways task force, we offer our perspectives on patient motivations for partnering with researchers to obtain results from mechanistic studies. We emphasize the challenges of balancing urgency with scientific rigor. We recognize the importance of such partnerships in addressing post-acute sequelae of SARS-CoV-2 infection (PASC), which includes ‘long COVID,’ through contrasting objective and subjective narratives. Long COVID’s prevalence served as a call to action for patients like us to become actively involved in efforts to understand our condition. Patient-centered and patient-partnered research informs the balance between urgency and robust mechanistic research. Results from collaborating on protocol design, diverse patient inclusion, and awareness of community concerns establish a new precedent in biomedical research study design. With a public health matter as pressing as the long-term complications that can emerge after SARS-CoV-2 infection, considerate and equitable stakeholder involvement is essential to guiding seminal research. Discussions in the RECOVER Mechanistic Pathways task force gave rise to this commentary as well as other review articles on the current scientific understanding of PASC mechanisms.